|
1
|
Long JS and Ryan KM: New frontiers in
promoting tumour cell death: targeting apoptosis, necroptosis and
autophagy. Oncogene. 31:5045–5060. 2012. View Article : Google Scholar
|
|
2
|
Mellier G, Huang S, Shenoy K and Pervaiz
S: TRAILing death in cancer. Mol Aspects Med. 31:93–112. 2010.
View Article : Google Scholar
|
|
3
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rieger J, Ohgaki H, Kleihues P and Weller
M: Human astrocytic brain tumors express AP02L/TRAIL. Acta
Neuropathol. 97:1–4. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Turner A, Li LC, Pilli T, Qian L, Wiley
EL, Setty S, et al: MADD knock-down enhances doxorubicin and TRAIL
induced apoptosis in breast cancer cells. PLoS One. 8:e568172013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Szliszka E, Czuba ZP, Kawczyk-Krupka A,
Sieron-Stoltny K, Sieron A and Krol W: Chlorin-based photodynamic
therapy enhances the effect of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) in bladder cancer cells. Med Sci
Monit. 18:BR47–BR53. 2012. View Article : Google Scholar
|
|
7
|
He Y, Wang JS, Zhang P, Zhang WJ, Huang QL
and Hua ZC: Synergistic apoptotic effect of the combination of
diosgenin and TRAIL on non-small-cell lung cancer cell line A549
evaluated with the Chou-Talalay method. Yao Xue Xue Bao. 48:45–51.
2013.(In Chinese).
|
|
8
|
Cai Y and Liu X, Huang W, Zhang K and Liu
X: Synergistic antitumor effect of TRAIL and IL-24 with complete
eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim
Biophys Sin (Shanghai). 44:535–543. 2012. View Article : Google Scholar
|
|
9
|
Bernardi S, Secchiero P and Zauli G: State
of art and recent developments of anticancer strategies based on
TRAIL. Recent Pat Anticancer Drug Discov. 7:207–217. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zauli G, Monasta L, Rimondi E, Vecchi
Brumatti L, Davanzo R, Demarini S and Secchiero P: Levels of
TNF-related apoptosis-inducing ligand (TRAIL) show a long-term
stability in the breast milk of mothers of preterm infants. J Hum
Lact. 29:350–353. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allen JE, Krigsfeld G, Mayes PA, Patel L,
Dicker DT, Patel AS, et al: Dual inactivation of Akt and ERK by
TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction,
and potent antitumor effects. Sci Transl Med. 5:171ra172013.
View Article : Google Scholar
|
|
12
|
Strebel A, Harr T, Bachmann F, Wernli M
and Erb P: Green fluorescent protein as a novel tool to measure
apoptosis and necrosis. Cytometry. 43:126–133. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gasparian ME, Chernyak BV, Dolgikh DA,
Yagolovich AV, Popova EN and Sycheva AM: Generation of new TRAIL
mutants DR5-A and DR5-B with improved selectivity to death receptor
5. Apoptosis. 14:778–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Du C, Fang M, Li Y, Li L and Wang X: Smac,
a mitochondrial protein that promotes cytochrome c-dependent
caspase activation by eliminating IAP inhibition. Cell. 102:33–42.
2000. View Article : Google Scholar
|
|
15
|
Luo X, Budihardjo I, Zou H, Slaughter C
and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c
release from mitochondria in response to activation of cell surface
death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mahalingam D, Szegezdi E, Keane M, de Jong
S and Samali A: TRAIL receptor signalling and modulation: Are we on
the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Chen W, Zeng W, Bai L, Tesfaigzi
Y, Belinsky SA and Lin Y: Akt-mediated eminent expression of c-FLIP
and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity
to lung cancer cells. Mol Cancer Ther. 7:1156–1163. 2008.
View Article : Google Scholar
|
|
18
|
Kaufmann T, Strasser A and Jost PJ: Fas
death receptor signalling: roles of Bid and XIAP. Cell Death
Differ. 19:42–50. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zaidi SF, Yamamoto T, Refaat A, Ahmed K,
Sakurai H, Saiki I, et al: Modulation of activation-induced
cytidine deaminase by curcumin in Helicobacter pylori-infected
gastric epithelial cells. Helicobacter. 14:588–595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Emam H, Zhao QL, Furusawa Y, Refaat A,
Ahmed K, Kadowaki M and Kondo T: Apoptotic cell death by the novel
natural compound, cinobufotalin. Chem Biol Interact. 199:154–160.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Refaat A, Abdelhamed S, Yagita H, Inoue H,
Yokoyama S, Hayakawa Y and Saiki I: Berberine enhances tumor
necrosis factor-related apoptosis-inducing ligand-mediated
apoptosis in breast cancer. Oncol Lett. 6:840–844. 2013.
|
|
22
|
Refaat A, Shahat A, Ehsan N, Yassin N,
Hammouda F, Abou Tabl E and Ismail S: Phytochemical and biological
activities of Crataegus sinaica growing in Egypt. Asian Pac
J Trop Med. 3:257–261. 2010. View Article : Google Scholar
|
|
23
|
Moon DO, Asami Y, Long H, Jang JH, Bae EY
and Kim BY: Verrucarin A sensitizes TRAIL-induced apoptosis via the
upregulation of DR5 in an eIF2α/CHOP-dependent manner. Toxicol In
Vitro. 27:257–263. 2013.PubMed/NCBI
|
|
24
|
Yamaguchi H and Wang HG: CHOP is involved
in endoplasmic reticulum stress-induced apoptosis by enhancing DR5
expression in human carcinoma cells. J Biol Chem. 279:45495–45502.
2004. View Article : Google Scholar
|
|
25
|
Abdelrahim M, Newman K, Vanderlaag K,
Samudio I and Safe S: 3,3′-diindolylmethane (DIM) and its
derivatives induce apoptosis in pancreatic cancer cells through
endoplasmic reticulum stress-dependent upregulation of DR5.
Carcinogenesis. 27:717–728. 2006.
|
|
26
|
Moon DO, Kang CH, Kang SH, Choi YH, Hyun
JW, Chang WY, et al: Capsaicin sensitizes TRAIL-induced apoptosis
through Sp1-mediated DR5 up-regulation: involvement of Ca(2+)
influx. Toxicol Appl Pharmacol. 259:87–95. 2012.PubMed/NCBI
|
|
27
|
Moon DO, Kim MO, Choi YH and Kim GY:
Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis
via extracellular signal-regulated kinase/Sp1-dependent DR5
upregulation and NF-kappaB inactivation. Mol Cancer Ther.
9:1583–1595. 2010. View Article : Google Scholar
|
|
28
|
Woo JS, Kim SM, Jeong CH, Ryu CH and Jeun
SS: Lipoxygenase inhibitor MK886 potentiates TRAIL-induced
apoptosis through CHOP- and p38 MAPK-mediated up-regulation of
death receptor 5 in malignant glioma. Biochem Biophys Res Commun.
431:354–359. 2013. View Article : Google Scholar
|
|
29
|
Sung B, Ravindran J, Prasad S, Pandey MK
and Aggarwal BB: Gossypol induces death receptor-5 through
activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer
cells to TRAIL. J Biol Chem. 285:35418–35427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ghosh AP, Klocke BJ, Ballestas ME and Roth
KA: CHOP potentially co-operates with FOXO3a in neuronal cells to
regulate PUMA and BIM expression in response to ER stress. PLoS
One. 7:e395862012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martín-Pérez R, Niwa M and López-Rivas A:
ER stress sensitizes cells to TRAIL through down-regulation of FLIP
and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis.
17:349–363. 2012.
|
|
32
|
Sung B, Prasad S, Ravindran J, Yadav VR
and Aggarwal BB: Capsazepine, a TRPV1 antagonist, sensitizes
colorectal cancer cells to apoptosis by TRAIL through
ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic
Biol Med. 53:1977–1987. 2012. View Article : Google Scholar
|
|
33
|
Kannappan R, Ravindran J, Prasad S, et al:
Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive
oxygen species/extracellular signal-regulated kinase/p53-mediated
upregulation of death receptors. Mol Cancer Ther. 9:2196–2207.
2010. View Article : Google Scholar
|
|
34
|
Wu GS, Kim K and el-Deiry WS: KILLER/DR5,
a novel DNA-damage inducible death receptor gene, links the
p53-tumor suppressor to caspase activation and apoptotic death. Adv
Exp Med Biol. 465:143–151. 2000.
|
|
35
|
Sung B, Park B, Yadav VR and Aggarwal BB:
Celastrol, a triterpene, enhances TRAIL-induced apoptosis through
the down-regulation of cell survival proteins and up-regulation of
death receptors. J Biol Chem. 285:11498–11507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park EJ, Choi KS, Yoo YH and Kwon TK:
Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to
TRAIL-induced apoptosis through p53-mediated PUMA upregulation and
ROS-mediated DR5 upregulation. Anticancer Drugs. 24:260–269. 2013.
View Article : Google Scholar
|
|
37
|
Safa AR, Day TW and Wu CH: Cellular
FLICE-like inhibitory protein (C-FLIP): a novel target for cancer
therapy. Curr Cancer Drug Targets. 8:37–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang P, Zhang J, Bellail A, Jiang W, Hugh
J, Kneteman NM and Hao C: Inhibition of RIP and c-FLIP enhances
TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal.
19:2237–2246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Junttila MR, Li SP and Westermarck J:
Phosphatase-mediated crosstalk between MAPK signaling pathways in
the regulation of cell survival. FASEB J. 22:954–965. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yerbes R, López-Rivas A, Reginato MJ and
Palacios C: Control of FLIP(L) expression and TRAIL resistance by
the extracellular signal-regulated kinase1/2 pathway in breast
epithelial cells. Cell Death Differ. 19:1908–1916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim J, Kang D, Sun BK, Kim JH and Song JJ:
TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically
modulated by the Src/CIN85/c-Cbl complex. Cell Signal. 25:372–379.
2013. View Article : Google Scholar
|
|
42
|
Antoon JW, Bratton MR, Guillot LM,
Wadsworth S, Salvo VA, Elliott S, et al: Pharmacology and
anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen
activated protein kinase. Am J Cancer Res. 2:446–458.
2012.PubMed/NCBI
|
|
43
|
Jane EP, Premkumar DR and Pollack IF:
Bortezomib sensitizes malignant human glioma cells to TRAIL,
mediated by inhibition of the NF-κB signaling pathway. Mol Cancer
Ther. 10:198–208. 2011.PubMed/NCBI
|
|
44
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Holsinger FC, Piha-Paul SA, Janku F, Hong
DS, Atkins JT, Tsimberidou AM and Kurzrock R: Biomarker-directed
therapy of squamous carcinomas of the head and neck: targeting
PI3K/PTEN/mTOR pathway. J Clin Oncol. 31:e137–e140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang G, Chen C, Yang R, Cao X, Lai S, Luo
X, et al: p55PIK-PI3K stimulates angiogenesis in colorectal cancer
cell by activating NF-κB pathway. Angiogenesis. 16:561–573.
2013.PubMed/NCBI
|
|
47
|
Martelli AM, Nyåkern M, Tabellini G,
Bortul R, Tazzari PL, Evangelisti C and Cocco L: Phosphoinositide
3-kinase/Akt signaling pathway and its therapeutical implications
for human acute myeloid leukemia. Leukemia. 20:911–928. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ciraolo E, Morello F and Hirsch E: Present
and future of PI3K pathway inhibition in cancer: perspectives and
limitations. Curr Med Chem. 18:2674–2685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chakravarti A, Zhai G, Suzuki Y, Sarkesh
S, Black PM, Muzikansky A and Loeffler JS: The prognostic
significance of phosphatidylinositol 3-kinase pathway activation in
human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alladina SJ, Song JH, Davidge ST, Hao C
and Easton AS: TRAIL-induced apoptosis in human vascular
endothelium is regulated by phosphatidylinositol 3-kinase/Akt
through the short form of cellular FLIP and Bcl-2. J Vasc Res.
42:337–347. 2005. View Article : Google Scholar
|
|
51
|
Reed JC: Bcl-2-family proteins and
hematologic malignancies: history and future prospects. Blood.
111:3322–3330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dole M, Nuñez G, Merchant AK, Maybaum J,
Rode CK, Bloch CA and Castle VP: Bcl-2 inhibits
chemotherapy-induced apoptosis in neuroblastoma. Cancer Res.
54:3253–3259. 1994.PubMed/NCBI
|
|
54
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: a link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reed JC: Bcl-2 family proteins: regulators
of apoptosis and chemoresistance in hematologic malignancies. Semin
Hematol. 34(Suppl 5): 9–19. 1997.PubMed/NCBI
|
|
56
|
Cristofanon S and Fulda S: ABT-737
promotes tBid mitochondrial accumulation to enhance TRAIL-induced
apoptosis in glioblastoma cells. Cell Death Dis. 3:e4322012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wahl K, Siegemund M, Lehner F, Vondran F,
Nüssler A, Länger F, et al: Increased apoptosis induction in
hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion
protein combined with bortezomib. Hepatology. 57:625–636. 2013.
View Article : Google Scholar
|
|
58
|
Wang JL, Liu D, Zhang ZJ, Shan S, Han X,
Srinivasula SM, et al: Structure-based discovery of an organic
compound that binds Bcl-2 protein and induces apoptosis of tumor
cells. Proc Natl Acad Sci USA. 97:7124–7129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hussein MR, Haemel AK and Wood GS:
Apoptosis and melanoma: molecular mechanisms. J Pathol.
199:275–288. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu X, Yue P, Khuri FR and Sun SY: p53
upregulates death receptor 4 expression through an intronic p53
binding site. Cancer Res. 64:5078–5083. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Takimoto R and El-Deiry WS: Wild-type p53
transactivates the KILLER/DR5 gene through an intronic
sequence-specific DNA-binding site. Oncogene. 19:1735–1743. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guan B, Yue P, Clayman GL and Sun SY:
Evidence that the death receptor DR4 is a DNA damage-inducible,
p53-regulated gene. J Cell Physiol. 188:98–105. 2001. View Article : Google Scholar
|
|
63
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz
M, Pugacheva E, Chumakov P, et al: Restoration of the tumor
suppressor function to mutant p53 by a low-molecular-weight
compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa
K, Chen PJ and Cheng AL: Dovitinib sensitizes hepatocellular
carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5
antibody, through SHP-1-dependent inhibition of STAT3. Biochem
Pharmacol. 83:769–777. 2012. View Article : Google Scholar
|
|
65
|
Chen KF, Tai WT, Liu TH, Huang HP, Li YC,
Shiau CW, et al: Sorafenib overcomes TRAIL resistance of
hepatocellular carcinoma cells through the inhibition of STAT3.
Clin Cancer Res. 16:5189–5199. 2010. View Article : Google Scholar : PubMed/NCBI
|
